Logo Logo

Publications by Würstlein, R.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 13.

Journal article

Montemurro, F.; Ellis, P.; Delaloge, S.; Würstlein, R.; Anton, A.; Button, P.; Lindegger, N.; Barrios, C. (2017): Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study. In: Cancer Research, Vol. 77

Würstlein, R.; Gluz, O.; Kates, R.; Persoon, M.; Wasmayr, M.; Knauer, M.; Koplmüller, R.; Grischke, E.-M.; Schem, C.; Thill, M.; Hasmüller, S.; Griesinger, F.; Köhler, A.; Otremba, B.; Schindlbeck, C.; Reimer, T.; Krauter, J.; Tome, O.; Otto, F.; Friedrichs, K.; Albert, U.-S.; Gebauer, G.; Nitz, U.; Harbeck, N. (2017): Results of multigene assay (MammaPrint (R)) and molecular subtyping (BluePrint (R)) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study. In: Cancer Research, Vol. 77

Tiefenthaller, A.; Brix, N.; Escudero, Pazos M.; Kost, B.; Rack, B.; Bodungen, V. von; Weissenbacher, T.; Würstlein, R.; Rühle, P.; Gaipl, U.; Harbeck, N.; Belka, C.; Scheithauer, H.; Lauber, K. (2017): Immunologische Aspekte der intraoperativen Radiotherapie beim Mammakarzinom nach brusterhaltender Operation. In: Strahlentherapie und Onkologie, Vol. 193: S72-S72

Wonhöfer, M.; Schindler, F.; Welslau, M.; Würstlein, R.; Harbeck, N.; Schinköthe, T. (2017): Elderly patients do benefit from eHealth support. In: Oncology Research and Treatment, Vol. 40: p. 264

Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E.-M.; Augustin, D.; Kümmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Würstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H.; Harbeck, N. (2017): De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. In: Annals of Oncology, Vol. 28, No. 11: pp. 2768-2772

Gluz, O.; Nitz, U.; Christgen, M.; Malter, W.; Clemens, M.; Reimer, T.; Nuding, B.; Aktas, B.; Stefek, A.; Ppllmanns, A.; Lorenz-Salehi, F.; Uleer, C.; Krabisch, P.; Kümmel, S.; Liedtke, C.; Shak, S.; Kates, R.; Würstlein, R.; Kreipe, H. H.; Harbeck, N. (2017): Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results. In: Annals of Oncology, Vol. 28

Corradini, S.; Schönecker, S.; Pazos, M.; Freislederer, P.; Reitz, D.; Ditsch, N.; Bodungen, V. von; Würstlein, R.; Harbeck, N.; Belka, C. (2017): DIBH radiotherapy in left-sided breast cancer patients using an optical surface scanning system. In: Breast, Vol. 32: S70-S71

Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Nuding, B.; Shak, S.; Würstlein, R.; Kreipe, H.; Harbeck, N. (2017): Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes. In: Breast, Vol. 32: S93-S93

Würstlein, R.; Grischke, E. M.; Gluz, O.; Kates, R.; Persoon, M.; Thill, M.; Hasmüller, S.; Knauer, M.; Pusch, R.; Harbeck, N. (2017): Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results. In: Breast, Vol. 32: S107-S107

Brain, E.; Corradengo, D.; Oriana, N.; Piccardo, A.; Matteucci, F.; Cortes, J.; Harbeck, N.; Würstlein, R.; Piris, A.; Alberini, J.-L.; Merlo, D. F.; Degenhardt, T.; Turbiez, I.; Madar, O.; Monti, M.; Cesaro, A.; Rivitti, E.; Rollandi, G. A.; Iacozzi, M.; Campazzi, E.; Campora, S.; Camporese, D.; Gennari, A. (2017): Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011. In: Cancer Research, Vol. 77

Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kümmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E.-M.; Haas, S. L. de; Deurloo, R.; Schumacher, J.; Würstlein, R.; Kreipe, H. H.; Gluz, O. (2017): The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). In: Cancer Research, Vol. 77

Schinköthe, T.; Harbeck, N.; Overkamp, F.; Weislau, M.; Würstlein, R.; Gieseler, F. (2016): CANKADO: First open eHealth platform for Oncology. In: Oncology Research and Treatment, Vol. 39: p. 23

Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H.; Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Oncology Research and Treatment, Vol. 39: p. 53

This list was generated on Mon Jun 24 05:48:14 2019 CEST.